☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Biocon
Biocon Biologics Enters into a Exclusive License Agreement with Sandoz for the Commercialization of Ogivri (biosimilar, trastuzuma...
February 9, 2024
PharmaShots Weekly Snapshots (October 09–13, 2023) _
October 14, 2023
Biocon Entered into a Commercialization Agreement with Juno Pharmaceuticals for Liraglutide to Treat Type 2 diabetes and Obesity i...
October 10, 2023
Biocon Reports P-I Study (RHINE-3) Results of Biosimilar Insulin
December 25, 2022
Biocon Entered into an Out-Licensing Agreement with Yoshindo to Commercialize bUstekinumab and bDenosumab in the Japan
October 17, 2022
Biocon to Acquire Viatris’ Biosimilars Assets for ~$3.335B
March 1, 2022
Load more...
Back to Home